M
ore than 420 000 persons in the United States require hemodialysis for end-stage kidney disease (1) . These patients face a high mortality rate: 169 per 1000 patient-years, compared with 30 per 1000 patientyears for transplant recipients (1) . Furthermore, the survival benefit of kidney transplant recipients is wellestablished (2, 3) and persists even with the use of kidneys from older donors with certain medical conditions (4) . However, a severe shortage of transplant organs exists. Depending on geography, waiting times for kidney transplantation may be as long as 10 years, and it is estimated that more than 50% of candidates on the waiting list will die before receiving a transplant (5, 6) . Thus, expansion of the donor pool would have a significant public health benefit.
Kidneys from deceased donors with hepatitis C virus (HCV) infection are underutilized. In the United States, between 2005 and 2014, a total of 2698 kidneys recovered from HCV-infected donors intended for transplantation were discarded (7) . A national study demonstrated that kidneys from HCV-infected donors are 2.9 times more likely to be discarded than kidneys of the same quality from non-HCV-infected donors, despite providing a survival benefit compared with remaining on dialysis (8) . The excess discarding may partly result from the lack of HCV-infected transplant candidates as well as the increase in deceased donors with HCV infection, probably because of the epidemic of drug overdose deaths (9 -11) . Donors with HCV generally are young and have few other medical comorbid conditions, and kidney transplantation outcomes from these donors have been excellent (12) .
In the past, transmission of HCV from donor to recipient was a serious concern. However, the landscape of HCV changed in 2013 with the introduction of directacting antiviral (DAA) agents with high cure rates, even in kidney transplant recipients (13) (14) (15) (16) (17) . In 2015, the once-daily, fixed-dose combination of the NS3/4A protease inhibitor grazoprevir (GZR) and the NS5A inhibitor elbasvir (EBR) was approved for use in persons with impaired renal function and HCV genotype 1 and 4 infection (18) . For genotype 2 and 3 infection, the NS5B inihibitor sofosbuvir (SOF) is highly active (19) . Addi-tional trials demonstrated the efficacy of GZR-EBR combined with SOF for genotype 3 infection (20, 21) .
Because of these developments, interest has been growing in the use of organs from HCV-infected donors for transplantation to non-HCV-infected recipients (that is, HCV D + /R Ϫ transplantation) (7, 22, 23) . The objective of our study was to explore a strategy to prevent HCV infection in noninfected recipients of kidneys from HCV-infected donors. As such, we investigated the feasibility and tolerability of GZR-EBR with or without SOF prophylaxis in an open-label single-center trial at Johns Hopkins University (EXPANDER [Exploring Renal Transplants Using Hepatitis C Infected Donors for HCVNegative Recipients]; ClinicalTrials.gov: NCT02781649).
METHODS

Study Population
Kidney transplant candidates on the deceaseddonor transplant waiting list at Johns Hopkins Hospital (JHH) aged at least 50 years were eligible if they were receiving hemodialysis or peritoneal dialysis or had had a glomerular filtration rate (GFR) less than 15 
Study Design
After providing written informed consent, participants were listed with the United Network for Organ Sharing (UNOS) with the status of "willing to accept an HCV + organ." The JHH transplant team then received offers from UNOS of kidneys from HCV-infected donors according to standard allocation policies. Eligible donors had to be between 13 and 50 years of age and have a positive result on a qualitative HCV nucleic acid test performed by the local Organ Procurement Organization (OPO) in accordance with standard UNOS policy. Other donor inclusion criteria were terminal serum creatinine level less than 265 μmol/L (3 mg/dL), projected cold ischemia time less than 36 hours, and preimplantation renal biopsy showing no evidence of chronic histologic changes in the donor kidney.
The OPOs performed donor HCV antibody and qualitative HCV nucleic acid testing using a U.S. Food and Drug Administration (FDA)-approved assay in accordance with UNOS-mandated deceased-donor testing. The results were available at the time of organ offer. Donor serum HCV RNA quantification and genotyping were performed in parallel with the transplantation, and results were available within 7 days of the procedure. Hepatitis C virus RNA was quantified by using the COBAS AmpliPrep/COBAS TaqMan HCV Test, version 2.0 (Roche Molecular Systems), or cobas HCV for cobas 6800 (Roche Molecular Systems) (lower limit of quantification [LLOQ] for both tests, 15 IU/mL). Hepatitis C virus genotyping was performed with a line probe assay (Quest Diagnostics), with reflex testing for NS5A resistance-associated substitutions (RASs) at positions 28, 30, 31, and 93 if genotype 1a was identified.
Grazoprevir, 100 mg, and EBR, 50 mg, were administered orally to participants while they waited to go to the operating room for the donor kidneys. Postexposure prophylaxis after HCV D + /R Ϫ transplantation varied according to the results of donor HCV testing. For recipients of kidneys from donors infected with HCV genotype 1a without NS5a RASs, genotype 1b, or genotype 4, GZR-EBR treatment was continued daily for 12 weeks. For recipients of organs from donors with genotype 1a infection with NS5a RASs, ribavirin was added to the GZR-EBR regimen for 16 weeks. For recipients of kidneys from donors infected with genotype 2 or 3, SOF, 400 mg/d, was added to the GZR-EBR regimen and continued for 12 weeks from the start of SOF treatment. If the donor's genotype could not be determined because of insufficient viral load, treatment with GZR-EBR alone was continued for 12 weeks.
Recipients were given induction immunosuppression with intravenous methylprednisolone and intravenous rabbit antithymocyte globulin, followed by mainte- 
Recipient Clinical Assessments
Other on-treatment assessments, performed at 1-to 4-week intervals, included physical examination, review of medications and safety assessments, and evaluation of renal and liver function and hemoglobin levels. Glomerular filtration rate was calculated by using the Chronic Kidney Disease Epidemiology Collaboration equation (24) . Posttreatment evaluation included safety assessments through the 12th week after treatment.
Recipient Virologic Assessment and Treatment Response
Recipient serum HCV RNA was measured with the COBAS Ampliprep TaqMan HCV Test, version 2.0, on day 0 before transplantation; on postoperative day 1; and at treatment weeks 1, 2, 3, 4, 8, and 12 through the end of treatment. The LLOQ was 15 IU/mL. After treatment, serum HCV RNA was measured at follow-up weeks 2, 4, 8, and 12. For recipients of kidneys from donors with HCV genotype 2 or 3, treatment week corresponds to week of treatment with the 3-drug combination (GZR-EBR + SOF).
Recipient Immunologic Assessments
Recipient HCV antibody testing was performed with the Advia Centaur system (Siemens) at baseline and follow-up week 12.
Hepatitis C virus-specific CD8 + T-cell responses were evaluated by interferon (IFN)-␥ enzyme-linked immunospot assay using a matrix of 73 peptides corresponding to previously described optimal cytotoxic T-lymphocyte epitopes, predominantly for genotype 1, with each peptide pool containing 7 to 12 peptides (25).
In brief, peripheral blood mononuclear cells were separated by using the Ficoll-Hypaque method. Enzymelinked immunospot plates were coated with 5 μg/mL of anti-human IFN-␥ monoclonal antibody (mAb; Mabtech) and kept at 4°C overnight. The plates were washed and blocked with 10% fetal bovine serum in Roswell Park Memorial Institute 1640 medium for 2 hours at 37°C, then 2 × 10 5 peripheral blood mononuclear cells were plated with 1 of 22 HCV peptide pools or control peptides against cytomegalovirus, Epstein-Barr virus, and influenza at a final concentration of 10 μg/mL. The plates were incubated at 37°C for 15 to 20 hours in a humidified incubator at 5% carbon dioxide. The following day, the plates were washed 7 times with phosphate buffered saline with 0.05% Tween 20 (SigmaAldrich). Detection antibody (biotinylated mouse antihuman IFN-␥ mAb [Mabtech] ) was added at a final concentration of 0.5 μg/mL, and the plates were kept at room temperature for 2 hours. They were then washed 4 times as described earlier, alkaline phosphatase-conjugated antibiotin mAb (Vector Laboratories) was added, and they were kept at room temperature for 2 hours. The plates were developed with NBT/BCIP Substrate Solution (ThermoFisher Scientific), and spots were counted by using the AID iSpot Spectrum (Advanced Imaging Devices). Only pools in which HCV-specific responses were greater than 50 spot-forming cells per million peripheral blood mononuclear cells were considered positive.
Statistical Analysis
The primary safety end point was the incidence of adverse events related to DAA treatment. The primary efficacy end point was the proportion of patients with an HCV RNA level less than LLOQ at follow-up week 12 among all participants who were enrolled and received study drugs. We used the Fisher exact test to determine whether high donor HCV RNA levels (>10 000 IU/ mL) were associated with recipient HCV antibody responses at follow-up week 8. We used a 2-sided ␣ of 0.05 to indicate a statistically significant difference. All 
Study Oversight
This study was approved by the Johns Hopkins Medicine Institutional Review Board and conducted in compliance with Good Clinical Practice guidelines. The FDA reviewed the study and granted it an investigational new drug application exemption.
Role of the Funding Source
The study drugs and funding were provided by Merck Sharp & Dohme. The investigators designed the study, conducted the protocol, and wrote the manuscript.
RESULTS
Recipient Characteristics
Fifteen candidates on the deceased-donor transplantation waiting list at JHH were approached for the study; the first 10 to consent were enrolled in the trial and received kidney transplants from donors with HCV infection. Median age of recipients was 71 years (interquartile range, 65 to 72 years) ( Table 1) . Eight recipients were men, and 8 were white. Median time on the waiting list before study enrollment was 4.2 months (interquartile range, 0.9 to 18.3 months); median time to transplantation after enrollment was 1 month (interquartile range, 0.7 to 2.0 months) ( Table 1) .
Donor Characteristics
Median age of accepted HCV-infected donors was 30 years (interquartile range, 23 to 35 years) ( Table 1) . Five donors were women, and all were white. The donors had brain death due to drug overdose (n = 6), trauma (n = 3), or a cardiovascular event (n = 1). The median Kidney Donor Profile Index score (on a scale from 0% to 100%, with higher values indicating a greater predicted risk for graft failure of an individual kidney) was 45% (interquartile range, 41% to 50%) ( Table 1 ). All donor kidneys were considered acceptable for transplantation on the basis of biopsy findings, including the absence of significant chronic histologic changes (Appendix Table 1 , available at Annals .org). Two donors (3 and 5) had received massive transfusions and had samples for HCV testing that met hemodilution criteria based on an FDA-approved calculation. Three of the organs (from donors 1, 6, and 10) underwent pulsatile perfusion at the local OPO after recovery from the donors and before being transported to JHH for transplantation. One donor kidney was from the local OPO, 1 kidney was from an OPO within the same UNOS region, and 8 kidneys were from OPOs outside the region.
Donor HCV Testing
Results of HCV antibody screening ( Table 2 ) and qualitative HCV nucleic acid testing with approved UNOS assays were positive in all 10 donors. Donor 3 had an HCV RNA that was not detected with subsequent quantitative HCV RNA testing; samples from this donor met criteria for hemodilution because the donor received massive transfusions before testing. Among the 9 donors with detectable viral loads, median HCV load was 62 400 IU/mL (range, 104 to 4 645 289 IU/mL) ( Table 2) . Donor HCV genotypes were 1a (n = 3), mixed 1a-3 (n = 1), and 2 (n = 2); in 4 cases, HCV genotype could not be determined because of insufficient HCV RNA levels.
Recipient HCV Treatment
Each of the 10 candidates received 1 dose of GZR-EBR while waiting to go to the operating room for the donor organ. The median time between the first GZR-EBR dose and reperfusion of the transplanted kidney was 5.1 hours (interquartile range, 3.5 to 7.7 hours). Seven recipients completed treatment with only GZR-EBR daily for 12 weeks, because their donors were infected with wild-type HCV genotype 1a or had a genotype that was unknown because of an insufficient HCV RNA level. Because no NS5A RASs were detected, none of the recipients needed to have ribavirin added to their treatment. Three recipients had SOF added to their GZR-EBR regimen after their donors' HCV infection was identified as non-genotype 1 or 4. None of the recipients required a delay in SOF treatment or modification in SOF dosage. Specifically, SOF therapy was initiated on postoperative day 12 in recipient 4, whose donor had mixed genotype 1a/3; on postoperative day 6 in recipient 8, whose donor had genotype 2; and on postoperative day 9 in recipient 7, whose donor had genotype 3 infection. Treatment continued with SOF in combination with GZR-EBR for an additional 12 weeks after initiation of SOF therapy. No recipient had a DAArelated adverse event. Shown are plasma HCV RNA levels before transplantation (baseline); during DAA treatment on POD1; at TW1, TW2, TW4, TW8, and TW12 after transplantation; and at FW4, FW8, and FW12 after DAA treatment. Lower limit of quantification is 15 IU/mL. DAA = direct-acting antiviral; FW = follow-up week; HCV = hepatitis C virus; POD = postoperative day; TW = treatment week.
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Recipient On-Treatment and Follow-up HCV RNA Seven of 10 recipients had an HCV RNA level below the LLOQ (15 IU/mL) at all time points (Table 2 and Figure 1 ). Two recipients had low levels of HCV RNA detected within 24 hours of transplantation (postoperative day 1) and undetectable HCV RNA at all other time points. Both of those recipients had donors with wild-type genotype 1a infection and HCV RNA loads greater than 1 million IU/mL (4.65 × 10 6 and 1.1 × 10 6 IU/mL, respectively). One patient received a kidney from a donor with HCV genotype 2 infection and began SOF treatment on postoperative day 6. This recipient had an HCV RNA load of 136 IU/mL on postoperative day 1 and 55 IU/mL at treatment week 1, with undetectable HCV RNA at all other time points during treatment. In all 10 recipients, HCV RNA was not detected at any of the follow-up visits after treatment with GZR-EBR with or without SOF. No participant had virologic or clinical evidence of chronic HCV infection.
Recipient Renal and Liver Function
The median creatinine level at follow-up week 12 was 92.8 μmol/L (1.05 mg/dL) (range, 79.6 to 176.8 μmol/L [0.9 to 2.0 mg/dL]), and the median estimated GFR was 63.5 mL/min/1.73 m 2 (interquartile range, 47.8 to 69.9 mL/min/1.73 m 2 ). The median cold ischemia time was 29 hours (interquartile range, 22.6 to 32.6 hours). Four recipients (1, 4, 5, and 10) had delayed graft function, defined as the need for renal replacement therapy in the first 7 days after transplantation. One of these recipients had a donor with HCV genotype 2 infection and required SOF treatment. He had a GFR greater than 60 mL/min/1.73 m 2 at the start of SOF therapy on postoperative day 12. High-grade proteinuria (defined as a urine protein creatinine ratio >1 or a urine dipstick result >1+) did not develop in any of the recipients during HCV prophylaxis through 6 months after transplantation (Appendix Table 2 , available at Annals.org). No recipient had acute rejection or required a kidney biopsy for any reason during follow-up.
One participant (recipient 4) had elevated aminotransferase levels 5 times greater than the upper limit of normal ( Figure 2 ) but no associated clinical symptoms. The patient's peak aspartate aminotransferase level was 109 U/L (postoperative day 9) and peak alanine aminotransferase level was 214 U/L (postoperative day 7); both levels decreased to the normal range by postoperative day 14 without any intervention. The donor's HCV RNA level was 46 733 IU/mL, the donor had mixed genotype 1a/3, and HCV RNA was detected in the recipient only on postoperative day 1 (<LLOQ). Sofosbuvir was added to the GZR-EBR regimen on postoperative day 12. Bilirubin levels remained within normal limits. No other recipient had an increase in aminotransferase or bilirubin levels during study follow-up.
None of the recipients required reoperation during the study period. Recipient 3 had a distal ureteral stricture that required management with a percutaneous nephroureteral stent on postoperative day 30, followed by serial balloon ureteroplasty and eventual stent removal.
Recipient HCV Antibody Responses
All recipients had negative HCV antibody test results at baseline. Five recipients had reactive HCV antibody test results at follow-up week 12, and 5 did not ( Table 2 ). For those who had reactive HCV antibody responses, the corresponding donor HCV genotypes were undetermined (n = 1), 1a (n = 2), 2 (n = 1), and 3 (n = 1). The median mean donor HCV RNA level for these recipients was 1.14 × 10 6 IU/mL, compared with 467 U/L IU/mL for those with nonreactive HCV antibody test results. Six HCV + /R Ϫ transplantations involved donors with an HCV RNA level above 10 000 IU/mL. No statistically significant association was found between donor HCV RNA levels greater than 10 000 IU/mL or HCV RNA detected in recipi- 
HCV T-Cell Responses
The development of T cells that recognize new HCV epitopes has provided a sensitive method to measure HCV replication, even in the absence of viremia, and that may be used to detect infection, reinfection, and superinfection (26) . Using a previously described technique (25), we tested peripheral blood mononuclear cells from all recipients for responses to 73 optimal HCV peptides in pools of 7 to 12 each. A positive response to a peptide pool was defined as the presence of more than 50 IFN-␥ spot-forming units per million cells. In addition, peripheral blood mononuclear cells were tested for responses to a mitogen and a pool of cytomegalovirus, Epstein-Barr virus, and influenza peptides. Responses to the mitogen and cytomegalovirus, Epstein-Barr virus, and influenza peptide pools were observed in all participants, demonstrating that posttransplantation immunosuppression did not completely inhibit T-cell responses. Four recipients had no positive response to HCV pools at either baseline or follow-up week 8 ( Figure 3) . A peptide pool was found in 3 recipients at treatment week 8 that had not been recognized before transplantation, potentially indicating new responses. We could not resolve the new responses to the individual peptides within each positive pool because of limited numbers of peripheral blood mononuclear cells. Overall, these data suggest that HCV T-cell responses may have developed in 3 transplant recipients and not in the other 7, with no change or increase in the HCV pools recognized.
DISCUSSION
This single-center, open-label, pilot study evaluated the transplantation of kidneys from HCV-infected donors to 10 non-HCV-infected recipients, with DAAs used as pre-and posttransplantation prophylaxis. The median wait time from study entry to transplantation was 1 month. No treatment-related adverse events occurred. Chronic HCV infection did not develop in any of the recipients.
In 2012, Flohr and colleagues (27) reported the use of kidneys from 13 donors with HCV antibody positivity for transplantation to older non-HCV-infected recipients with no HCV treatment. Donor-to-recipient HCV transmission occurred in 7 of the 13 cases (54%); these 7 recipients had a high rate of transaminitis (6 of 7), with 1 HCV-related liver death occurring 5 months after transplantation. In this series, results from donor HCV nucleic acid testing were not available, so some donors might not have had active HCV infection.
More recently, with the advent of IFN-free DAAs, Goldberg and colleagues (28) In this study, the recipients were monitored for HCV viremia starting at postoperative day 3. Once HCV RNA was detected, GZR-EBR treatment was initiated for a 12-week course. Donor-to-recipient HCV transmission occurred in 100% of recipients, with 2 cases of elevated aminotransferase levels. However, all recipients eventually achieved a sustained virologic response, at week 12 after treatment.
To our knowledge, our study is the first to explore a strategy of DAA treatment as pre-and postexposure prophylaxis for HCV D + /R Ϫ transplantation. This approach was safe and effective in preventing chronic HCV infection in all our recipients. Moreover, it may also have prevented acute HCV infection in some patients. In our study, 5 recipients never had a detectable level of plasma HCV RNA, 4 had a low level only on postoperative day 1, and 1 had a low level detected up to 1 week after transplantation. No symptoms or clinical consequences were observed in patients with low-level viremia (peak, 136 IU/mL). Preventing acute viral hepatitis early after transplantation is ideal, because many kidney transplant recipients receive lymphocyte-depleting induction immunosuppression.
Our study design allowed us to use organs from donors infected with any HCV genotype and did not require additional virologic or genotypic assays at the time of organ offer and allocation. Three donors in our study were found to have non-genotype 1 infection, which is consistent with trends in the HCV epidemic among young persons who inject opiates in the United States (29, 30). In THINKER, 50% of potential kidney donors were excluded because of non-genotype 1 HCV infection, which was detected by using a rapid genotype assay (31). The potential for a high rate of organ discarding and the limited availability of rapid genotype testing represent may limit this approach. The number of positive peptide pools identified for each recipient before transplantation and at FW8 is shown. T-cell responses were measured by interferon-␥ enzyme-linked immunospot using a matrix of 6 peptide pools containing overlapping peptides of optimal cytotoxic T-lymphocyte HCV epitopes. Pools with more than 50 spotforming cells per million peripheral blood mononuclear cells were considered positive. FW = follow-up week; HCV = hepatitis C virus.
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All donors in our study were relatively young and white; 6 had died of drug overdose, reflecting the national opioid epidemic. Of note, only 3 of the 10 donors had HCV genotype 1a infection. Four donors had very low HCV RNA levels with an indeterminate genotype. In the case of donor 3, the qualitative HCV RNA result may have been a false-positive, or the quantitative HCV RNA result may have been a false-negative due to hemodilution, because this donor received massive transfusions before testing. The 3 donors who had low but quantifiable HCV RNA levels may have aquired HCV infection only recently. Studies of the acute-phase hepatitis C viral dynamics among injection drug users demonstrate intermittent low-level viremia as well as periods of undetectable viremia in this early stage (32, 33) .
We performed several virologic and immunologic studies to further explore whether our pre-and posttreatment strategy truly prevented infection or whether it simply treated an established early infection. Only 5 recipients ever had HCV RNA detected after transplantation, and at very low levels (peak, 136 IU/mL), which arguably might represent viral transfer from the donor kidney rather than production of new HCV particles from the recipient's liver. However, we detected new HCV antibody responses in 5 of 10 recipients. An HCV antibody response did not correlate with donor HCV genotype, donor HCV RNA level, or the presence of low-level HCV viremia in recipients after transplantation; however, our sample size was small. Whether these antibodies indicate infection of the recipient's liver or a response to virus or antigen carried over with the donor organ is unclear. Three recipients had an increased T-cell responses to HCV peptide pools; however, these recipients all had positive T-cell responses detected before transplantation, indicating that these responses may have been cross-reactive rather than specific to HCV. We could not resolve the pools into individual peptides because of a limited number of peripheral blood mononuclear cells, which made it difficult to determine whether responses to new T-cell epitopes developed that would have provided stronger evidence that HCV replication occurred in the recipients. In the end, it is difficult to conclude whether our strategy functioned as true prevention in all recipients or as very early treatment of HCV infection. Nonetheless, our prophylactic approach to HCV D + /R Ϫ transplantation represents an alternative to delaying treatment until viral replication has increased to levels necessary to detect viremia.
Our study had limitations. It was a single-center nonrandomized trial with a small number of participants. Transplant recipients were older, predominantly male, and white; however, on the basis of other DAA trials, there is no reason to believe that this strategy would be less effective in other age groups, women, or members of other racial groups. For our studies of HCV T-cell responses, we could not resolve individual peptides recognized within each pool because of limited peripheral blood mononuclear cells.
In conclusion, this open-label nonrandomized study showed that DAA prophylaxis for non-HCVinfected recipients of kidneys from HCV-infected donors was safe and well-tolerated. No treatment-related adverse events or cases of chronic HCV occurred. This strategy should be studied further in carefully monitored clinical trials. If confirmed in larger studies, this approach should markedly expand organ options and reduce mortality for kidney transplant candidates without HCV infection. 
